Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of MK-6096 as Augmentation for Major Depressive Disorder
2011-005200-15Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of filorexant in major depressive disorder (MDD), sponsored by Merck & Co.. Started Jan 2012; status: completed.
02
Drugs
filorexant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2011-005200-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005200-15.